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the cardiac action potential is critical
for normal excitability. Abnormalities
in channel function such as those due
to congenital defects, or that are due
to acquired mechanisms (i.e., drug-
induced), can compromise the action
potential waveform and potentially
lead to life-threatening arrhythmias
(1). Of particular importance is the cur-
rent through Kv11.1 channels, which is
the subject of the two companion arti-
cles of Perissinotti et al. (2) and Guo
et al. (3) in this issue of the Biophysical
Journal. Kv11.1 channels are encoded
by the human ether-a`-go-go related
gene (hERG). Block of Kv11.1
is known to be the mechanism of
arrhythmic action of prolongation
of QT interval and arrhythmogenesis
of a significant number of drugs (4).
Accordingly, there is a significant in-
terest in the pharmacology of Kv11.1
channels, and all investigational new
drugs (regardless of target and mecha-
nism(s) of action) must be tested for
HERG activity before proceeding to
phase-II clinical trials (5).
Two kinetically distinct delayed
rectifier currents are active in cardiac
myocytes: a rapidly activating (IKr;
hERG/Kv11.1) and a slowly activatinghttp://dx.doi.org/10.1016/j.bpj.2015.01.011
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0006-3495/15/03/1309/3 $2.00(IKs), potassium current (6). The gene
underlying the latter current is KCNQ1,
which, when coexpressed withKCNE1,
is responsible for the b-subunits of
the channel. Genetic defects in either
of these two channels are associated
with action potential prolongation,
arrhythmias, and sudden cardiac death.
Restoring repolarization to normal
duration through pharmacologically
increased activation of hERG is re-
garded as being ofmajor clinical impor-
tance for the treatment of both acquired
(e.g., drug- or chemical-induced) and
genetically based prolongation of the
QTinterval. Compared to other voltage-
gated potassium channels, Kv11.1
channels have two distinguishing char-
acteristics: gating and the molecular
architecture of the pore. These unique
properties of Kv11.1 channels have
important implications on drug-channel
interactions (4,7). The pore structure
and its lability play a major role in
the promiscuous binding ability that
makes it so susceptible to block by
wide ranges of compounds (8). This
open channel binding is thought to
depend on inactivation of the channel
and conformational changes involving
specific residues lining the pore (4).
The potential mechanisms by which
channel activation can be achieved are
less clear. However, they generally fall
into two classes, i.e., those that act by
increased trafficking and retention to
the cell surface (not discussed here),
and those that act more acutely by inter-
acting with inactivation or activation
processes. These Kv11.1 channel acti-
vators are grouped as Type 1 or Type
2, depending on the primary effect
of the compound on Kv11.1 gating.
Type-1 agonists primarily slow the
rate of channel deactivation, and the
first member described in this group
is RPR260243 (4). In contrast, com-
pounds that belong to Type 2 have a
main effect that is targeted to the
Kv11.1 channel inactivation process
(4,7,9). It must be noted nevertheless
that some Kv11.1 channel activators
(e.g., KB130015) have mechanisms of
action that preclude their classificationas either Type 1 or Type 2 (see Vanden-
berg et al. (4)).
A major challenge for research and
clinical practice is to define what con-
stitutes a safe way to correct prolonged
repolarization in cardiac muscle.
Drugs that increase repolarizing cur-
rent by interfering with hERG inacti-
vation also mimic the effects of the
arrhythmogenic short-QT syndrome
(10), casting some doubt on the safety
and efficacy of this approach. Perissi-
notti et al. (2) and Guo et al. (3)
examine the molecular basis of a drug
that acts by increasing current through
changing the kinetics of both activa-
tion and inactivation. Whether this
approach is safe will depend ultimately
on the kinetic behavior of channel
gating for drug binding to states that
are only visited transiently during the
cycle of cardiac electrical events, and
to whether the altered speed of activa-
tion changes the shape (e.g., triangula-
tion) of the action potential and its
restitution properties in a safe way.
This is no longer merely an academic
exercise; new guidelines for drug
testing and approval are being updated
by the FDA through the comprehensive
in vitro proarrhythmic assay initiative,
which will require in silico validation
of mechanism and safety (5).
Knowledge of the gating properties
of hERG and its interaction with
state-dependent drugs requires appre-
ciating this as a chemical reaction.
Understanding the implications of
these chemical reactions during the
action potential requires reduction of
this model to sufficient simplicity
for large-scale action potential and
tissue-level simulations. In the past
two decades, a variety of such models
of hERG have been proposed, ranging
from the Hodgkin-Huxley formalism,
to simple linear Markov and to highly
complex Markovian schemes contain-
ing several components of the closed,
open, and inactivated states of the
channel (4,11). Already it is clear that
1310 Rasmusson and Anumonwothe details of these models are of major
importance. A comparative analysis
of five distinct hERG models showed
that Hodgkin-Huxley-type formulation
could not adequately reproduce gating
of Kv11.1 channels (11), and required
at least five states (i.e., three closed,
one open, and one inactivated state)
and that a voltage-independent step
was required between some of the
closed states. Such an approach was
used in the Perissinotti et al. (2) article.
Given the complexity in Kv11.1 chan-
nel-gating kinetics, aspects of which
are daunting to examine experimen-
tally, the combination of strategies
used by Perissinotti et al. (2) and Guo
et al. (3) to uncover the activation
gating characteristics is particularly
impressive. The comprehensive ap-
proach used produces well-justified
and appropriate mathematical models
for incorporating channel and drug
structure into future simulations at
higher levels of integration.
As part of the development of new
drugs, high-throughput techniques
were used initially to identify, rather
serendipitously, a list of partial agonists
(i.e., activators) of Kv11.1 channels
(4,9,12). The identified compounds
showed distinctive mechanisms of
action, possibly reflecting the manner
in which each compound differentially
interacted with the Kv11.1 channel
molecule. In 2006, a novel small
organic molecule was developed to
test whether the drug could increase
the activity of human Kv11.1 channels
(7). The pharmacologic compound is
a diphenylurea compound (1,3-bis-(2-
hydroxy-5-trifluoromethyl-phenyl)-
urea, and was dubbed ‘‘NS1643’’. Cell
electrophysiology experiments showed
that NS1643 increased currents through
heterologously expressed Kv11.1
channels, as well as prolong postrepo-
larization refractory time in isolated
cardiac myocytes (7). NS1643 caused
a hyperpolarization shift in voltage-
dependence of channel activation.
Moreover, by shifting C-type inactiva-
tion to depolarized potentials, Kv11.1
tail-current amplitude was significantly
increased. There is evidence thatBiophysical Journal 108(6) 1309–1311NS1643 effects on channel inactivation
may involve regions within the pore
helix, and probably are components
important for modulating the inactiva-
tion gate (4). A later study was carried
out to elucidate the precise binding
pocket of NS1643 (13). In the study, a
combination of structure- and model-
guided mutagenesis was used to deter-
mine amino-acid residues important
for Kv11.1-NS1643 interactions, with
potential implications on the drug-
induced effects on the channel. In
this issue of the Biophysical Journal,
the two notable studies (2,3) have
probed further, quite comprehensively,
NS1643 and Kv11.1 channel interac-
tions. In these studies the investigators
used a combination of electrophysio-
logical, theoretical, spectroscopic, and
biochemical methods to enhance our
understanding of activation of Kv11.1.
Perissinotti et al. (2) combined
results of electrophysiological analysis
on wild-type (WT) and mutant (L529I)
Kv11.1 channels with the results of
molecular and kinetic modeling. The
electrophysiological data show that
whereas WT and L529L channels
have similar channel-gating kinetics,
their interactions with NS1643 are dis-
similar. It was shown that in contrast
to the WT channel, in mutant channels,
NS1643 significantly flattened the
slope of the current voltage, while
having little or no effect on the V1/2
of activation. Based on the drug effects
on channel gating, the investigators
posit that NS1643 binds to early closed
states (presumably C3, C2) and open
states (O), in a manner suggestive
that the drug-channel interactions
modulate gating transitions preceding
opening of channel activation gate.
The second submission, by Guo
et al. (3), further examined this pro-
posed mechanism. Voltage-clamp fluo-
rimetry analysis showed that NS1643
reduced the voltage sensitivity of
Kv11.1 (L529I) channels, compared
to the WT channel. To examine the
possible role of nonpolar residues in
the neighborhood of L529, i.e., within
the S4 helix, mutagenesis was carried
out on K525, I567, and L529 residuesof the Kv11.1 channel. In single and
double substitution-mutant forms of
the channel, NS1643-dependent chan-
nel activation and the molecular
modeling details have led to a hypoth-
esis that mutation-induced conforma-
tional change (an apparent kink in the
S4) on Kv11.1 enhances NS1643 affin-
ity to the channel, and may probably
explain the action of hERG channel
pharmacologic activators.
The elegance of this model notwith-
standing, a number of limitations are
immediately evident, some of which
were acknowledged by the investiga-
tors. In their conclusions, the investiga-
tors recognize that their contention
may be an oversimplification of the
rather complex molecular rearrange-
ments that must precede opening of
the activation gate of the channel.
Nevertheless, the two contributions
indeed provide compelling arguments
for underlying mechanistic principles
that possibly govern NS1643-depen-
dent activation of Kv11.1 channels.
These studies, based on a multidisci-
plinary approach, clearly provide
exciting pointers that will be quite
valuable for further studies on hERG
channel activators and long-QT thera-
peutic intervention.ACKNOWLEDGMENTS
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